A randomized controlled trial of buprenorphine in the management of short‐term ambulatory heroin withdrawal
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aim To determine whether buprenorphine is more effective than clonidine and other symptomatic medications in managing ambulatory heroin withdrawal. Design Open label, prospective randomized controlled trial examining withdrawal and 4‐week postwithdrawal outcomes on intention‐to‐treat. Setting Two specialist, out‐patient drug treatment centres in inner city Melbourne and Sydney, Australia. Participants One hundred and fourteen dependent heroin users were recruited. Participants were 18 years or over, and with no significant other drug dependence, medical or psychiatric conditions or recent methadone treatment. One hundred and one (89%) participants completed a day 8 research interview examining withdrawal outcomes, and 92 (81%) completed day 35 research interview examining postwithdrawal outcomes. Interventions Participants randomized to control (n = 56) (up to 8 days of clonidine and other symptomatic medications) or experimental (n = 58) (up to 5 days of buprenorphine) withdrawal groups. Following the 8‐day withdrawal episode, participants could self‐select from range of postwithdrawal options (naltrexone, substitution maintenance, or counselling). Measurements Retention in withdrawal; heroin use during withdrawal; and retention in drug treatment 4 weeks after withdrawal. Secondary outcomes Withdrawal severity; adverse events, and heroin use in the postwithdrawal period. Findings The experimental group had better treatment retention at day 8 (86% versus 57%, P = 0.001, 95% CI for numbers needed to treat (NNT) = 3–8) and day 35 (62% versus 39%, P = 0.02, 95% CI for NNT = 4–18); used heroin on fewer days during the withdrawal programme (2.6 ± 2.5 versus 4.5 ± 2.3, P < 0.001, 95% CI = 1–2.5 days) and in the postwithdrawal period (9.0 ± 8.2 versus 14.6 ± 10, P < 0.01, 95% CI = 1.8–9.4); and reported less withdrawal severity. No severe adverse events reported. Conclusions Buprenorphine is effective for short‐term ambulatory heroin withdrawal, with greater retention, less heroin use and less withdrawal discomfort during withdrawal; and increased postwithdrawal treatment retention than symptomatic medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Self-report among injecting drug users: A review
Darke, S. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00028-3 · Cited by 1,141 · cited 1×
“Drug use measures in the postwithdrawal period were limited to self-report; however, self-report data are usually considered reliable when collected by research assistants not involved in clinical services, and with no punitive consequences for subjects reporting heroin use (Darke 1998).”
BackgroundJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 1×
“Headache, nausea, drowsiness, sweating and lethargy were reported by more than 5%, as has been reported previously (Ling et al. 1998).”
Are detoxification programmes effective?
Mattick, R. P., & Hall, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90215-9 · Cited by 196
A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence
Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9656834.x · Cited by 150 · cited 1×
“One such approach incorporates the use of buprenorphine, a partial opioid agonist registered recently for the treatment of opioid dependence (Bickel & Amass 1995; Barnett et al. 2001; Lintzeris et al. 2001; West et al. 2000).”
Cited by
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Medication Treatment of Opioid Use Disorder
Bell, J., & Strang, J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.06.020 · Cited by 328
Self-citationBuprenorphine for the management of opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002025.pub4 · Cited by 297
Sublingual Buprenorphine Is Effective in the Treatment of Chronic Pain Syndrome
Malinoff, H. L., Barkin, R. L., & Wilson, G. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000160935.62883.ff · Cited by 121
Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings
Mintzer, I. L., Eisenberg, M., Terra, M., MacVane, C., Himmelstein, D. U., & Woolhandler, S. (2007) · The Annals of Family Medicine · doi:10.1370/afm.665 · Cited by 117
Metadata
- Authors
- Lintzeris, N., Bell, J., Bammer, G., Jolley, D. J., & Rushworth, L.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2002-10-31
- Volume
- 97
- Issue
- 11
- Pages
- 1395-1404
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2152100136
- Cited by
- 102
- References
- 5
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized controlled trial of buprenorphine in the management of short‐term ambulatory heroin withdrawal. https://app.cochat.ai/papers/10.1046/j.1360-0443.2002.00215.x
- The paper
- Lintzeris, N., Bell, J., Bammer, G., Jolley, D. J., & Rushworth, L. (2002). A randomized controlled trial of buprenorphine in the management of short‐term ambulatory heroin withdrawal. Addiction. https://doi.org/10.1046/j.1360-0443.2002.00215.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.